Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCb is a non-specific term that refers to at least two distinct substances mentioned in clinical contexts: glucocerebrosidase (GCB), specifically Gene-Activated® human glucocerebrosidase (GA-GCB, also known as velaglucerase alfa), and GCB-70, a green coffee extract. Velaglucerase alfa is an enzyme replacement therapy used to treat Gaucher disease, a rare lysosomal storage disorder caused by a deficiency of the glucocerebrosidase enzyme. It works by replacing the deficient enzyme, thereby preventing the accumulation of glucocerebroside within macrophages. GCB-70 is a nutraceutical derived from raw coffee beans, and it has been clinically evaluated for its efficacy in weight loss, acting as a slimming aid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GCb.